Agreement between sarcopenia screening tools in colorectal cancer patients undergoing chemotherapy

Introduction Evidently, colorectal cancer and chemotherapy increase the risk of Sarcopenia. Therefore, sarcopenia screening is vital to prevent the adverse effect of Sarcopenia. However, there is a lack of studies regarding sarcopenia screening tools in the colorectal patient in Indonesia. Therefore, this study's objective was to determine the proportion of patients at sarcopenia risk utilizing different screening tools and agreement between those screening tools in patients with colorectal cancer undergoing chemotherapy. Method A cross-sectional study of adult patients with colorectal cancer receiving IV chemotherapy at Kariadi General Hospital, Indonesia, was conducted. Risk of Sarcopenia utilized screening tools SARC-F, SARC-Calf (33 and 34) and SARC-Calf 31. The Kappa coefficient was calculated to identify agreement between the three tools. Result This study included 89 colorectal patients undergoing chemotherapy, 53.9 % were male, and 82 % were malnourished. The prevalence of sarcopenia risk using SARC-F, SARC-Calf 31 and SARC-Calf (33 and 34) were 15.7 %, 29.2 % and 40.4 %, respectively. The agreement between SARC-F and SARC-Calf 31, SARC-Calf 33 and 34 was 'Fair', with k=0.3 and 0.29, respectively. SARC-Calf 31 and SARC-Calf had a substantial agreement (k=0.64) Conclusion There was a high proportion of patients at risk of Sarcopenia using different screening tools. However, there was a variation between the proportion of sarcopenia risk and agreement between the three screening tools. Thus, further validation of sarcopenia risk screening tools for colorectal cancer patients in Indonesia is vital.